Omalizumab is a humanized monoclonal anti-immunoglobulin E (IgE) antibody indicated in Europe for the treatment of uncontrolled severe persistent allergic (IgE-mediated) asthma despite optimal therapy with inhaled corticosteroids and long-acting b 2 agonists.
Introduction
Asthma represents one of the most common chronic diseases. 1, 2 In the majority of patients control of asthma as defined by guidelines can be achieved with inhaled corticosteroids and b2-agonists.
3e5 However, patients with severe persistent asthma who are inadequately controlled despite treatment according to current asthma guidelines are at high risk of severe exacerbations and asthma-related mortality and represent the greatest unmet medical need among the asthmatic population today. 6, 7 Recently, the recombinant humanized monoclonal antiimmunoglobulin E (IgE) antibody omalizumab has been introduced as an add-on treatment for patients with inadequately controlled persistent allergic asthma despite GINA step 5 therapy. IgE plays a central role in the pathogenesis of allergic asthma. 8 After sensitization, atopic patients respond to allergen exposure through a number of IgEdependent mechanisms, 8 making IgE a novel and attractive target for anti-allergic and anti-asthmatic treatments. 9 Omalizumab interrupts the allergic cascade by binding free serum IgE. 10 Clinical trials confirm that in patients with allergic asthma who have a significant unmet need despite best available therapy omalizumab as add-on therapy reduced asthma symptoms, clinically significant asthma exacerbations and emergency visits as well as hospitalizations due to asthma. 8,9,11e17 In 2005, omalizumab has been approved by the European Medicines Agency (EMEA) as add-on therapy for patients 12 years and older with severe persistent allergic asthma who demonstrate a positive skin prick test or an in vitro reactivity to a perennial aeroallergen, a reduction in lung function (FEV 1 < 80%), frequent daily symptoms or nightly awakenings, multiple severe asthma exacerbations despite treatment with high doses of inhaled corticosteroids and long-acting-b 2 agonists, and a treatable IgE burden as defined by total serum IgE and body weight within the therapeutic window.
Aim of the present prospective post-marketing surveillance trial was to verify the efficacy and tolerability of omalizumab in a real-life setting following the introduction of the drug to the German market in October 2005. It describes the characteristics of patients and the real-life effectiveness of omalizumab in the first large group of patients who received this treatment in Germany.
Methods Patients
This observational study was performed according to Good Clinical Practice (GCP) standards, the declaration of Helsinki and was approved by the local ethics committee. All patients included in this study gave written informed consent.
In the period between November 2005 and February 2007 280 patients with uncontrolled severe persistent allergic asthma were treated with omalizumab and were prospectively investigated by 135 physicians in Germany. Patients were selected for add-on therapy with omalizumab as approved by the EMEA and as recommended by German 18 and international guidelines 2 based on age (patients !12 years), positive skin prick test or in vitro reactivity against at least one perennial allergen, reduced lung function (FEV 1 < 80% pred.), frequent daily symptoms or nocturnal awakenings, severe asthma exacerbations despite high doses of inhaled corticosteroids and long-acting b 2 -agonists, total serum IgE between 30 and 700 IE/ml, and body weight between 20 and 150 kg.
Study design
Due to its mechanism of action, the EMEA recommends that omalizumab treatment effectiveness be assessed after 16 weeks of treatment. 19 Consequently, patients were investigated prior to start of treatment with omalizumab as well as after 4 and 6 months of the treatment phase. At the initial visit physicians completed a questionnaire regarding the 12 monthperiod prior to omalizumab treatment (baseline data) to collect demographics (date of birth, sex, smoking status), abnormal pulmonary function defined as an FEV 1 < 80% of predicted, asthma-related treatments (inhaled corticosteroids, long-acting b 2 -agonists, oral corticosteroids, sustainedrelease theophylline, leukotriene receptor antagonists), daily symptoms, nightly awakenings, days off school or work, number of exacerbations (as defined by FEV 1 < 60% of personal best, intermittent treatment with oral corticosteroids, unscheduled health care visits, emergency treatments, hospitalizations due to asthma), hospitalizations, unscheduled health care visits, and omalizumab dosing information (body weight of patient, total IgE). Quality of life (QoL) was assessed using the Mini Adult Asthma Quality of Life Questionnaire (Mini-AQLQ). 20 The quality of life score was calculated using the following equation: total score Z total (question 1equestion 10)/number (question 1equestion 10). Both patients and investigators independently evaluated treatment effectiveness and tolerability of omalizumab after 4 and 6 months.
4 and 6 months after the start of omalizumab treatment physicians completed questionnaires providing information about treatment discontinuation (date, reason), date of last clinical evaluation whilst still under treatment, modification of asthma-related treatments (inhaled corticosteroids, long-acting b 2 -agonists, oral corticosteroids, slow-release theophylline, leukotriene receptor antagonists), daily asthma symptoms/nocturnal awakenings, and adverse events suspected to be linked to omalizumab treatment. Lung function changes were recorded as categorical variables, i.e. improved or deteriorated compared with baseline. At the end of the trial period after 6 months patients again provided information about days off school or work, and the number of exacerbations. As is typical for postmarketing surveillance trials and to reflect the real-lifesituation in daily clinical routine instructions concerning diagnostic and therapeutic procedures were not issued.
Medication and dosing
Individual omalizumab doses were calculated according to a dosing table based on the patient's individual IgE load, i.e. on pre-treatment body weight and total serum IgE level at screening, as previously described. 21 Depending on the omalizumab dose, the drug was administered by subcutaneous injection every 2 or 4 weeks. There were no restrictions on doses of ICS and LABA (taken separately or as a fixed combination) and other concomitant asthma medications during the treatment period.
Statistical analysis
In the study population, effectiveness of omalizumab over the treatment period as reflected by the reduction of exacerbations was evaluated in all patients with follow-up data. Analyses were descriptive and annual rates calculated using patient-years. All patients treated with omalizumab at least once were considered for tolerability evaluation by monitoring of adverse events. Due to the observational character of the study neither a primary endpoint was defined nor a statistical power calculation was performed. Data analysis was performed by using SAS â software. Data description was primarily based on means and standard deviation or medians and quartiles for continuous endpoints and based on frequencies for categorical endpoints. The resulting pair wise comparisons were based on Wilcoxon test or t test and on Fishers exact test (p values < 0.05 indicate local statistical significance).
Results

Study population
During the period between November 2005 and February 2007, 280 patients with physician-diagnosed severe persistent allergic asthma with a mean age of 43.9 AE 16.3 years (range 10e78 years, 3 patients 12 years) were followed up for a mean of 195 AE 60 days ( Table 1 ). All patients had a documented sensitization to at least one perennial aeroallergen. 243 patients (86.8%) suffered from additional allergic diseases. Accordingly, in 226 patients (80.0%) attempts were made to reduce allergen exposure (e.g. mattress covers in 75.2% of patients). The median IgE level prior to treatment with omalizumab was 235.0 IU/ml (interquartile range 130e457 IU/ml, min. 16 IU/ml, max. 5820 IU/ml), mean body weight was 73.1 AE 17.2 kg (range 27e150 kg). All patients were treated with high doses of inhaled corticosteroids and long-acting b 2 -agonists. The majority of patients (90.4%) were treated by at least 2 and upto 7 different classes of drugs. In retrospect 271 patients (96.8%) fulfilled the criteria for severe allergic asthma according to the omalizumab label (Table 1) .
Pre-treatment asthma control
In the 12 months prior to initiation of omalizumab treatment 269 patients (96.1%) reported daily asthma symptoms and 242 patients (86.4%) nightly awakenings. Nearly all patients (90.0%) had experienced frequent severe asthma exacerbations (mean 4.5 AE 7.5 exacerbations/year), 67 patients (23.9%) were hospitalized due to exacerbations. In addition, 238 patients (85.0%) reported on average 4.4 AE 4.6 unscheduled health care contacts or emergency room visits due to asthma in the year prior to treatment with omalizumab. 171 patients (61.1%) had not been able to go to work or school for at least one day. Total pre-treatment quality of life score was 2.9 AE 0.9 points (Table 2) .
Asthma control after 4 and 6 months of omalizumab treatment
Patients were administered a median of 450 mg omalizumab per month (range 150e850 mg per month). In 43 patients (14.9%) the IgE load was outside the recommended Upon reevaluation of patients after 4 months there was a marked reduction of daily asthma symptoms and nocturnal awakenings by 69.1% and 72.3% resp. (p < 0.001 resp.). After 6 months there was a further reduction in daily symptoms and nocturnal awakenings down to a total reduction of 79.6% and 86.4% resp. (p < 0.001 resp.). During therapy with omalizumab concomitant allergy manifestations decreased significantly by 80.6% after 4 months and by 87.1% after 6 months (p < 0.001, both comparisons). In 177 patients (63.4%) lung function improved after 4 months and in 157 of 241 patients (65.1%) after 6 months. Compared with the 12 month pre-treatment period the rate of severe asthma exacerbations decreased by 82.0% to a mean of 0.3 AE 0.8 exacerbations/year (rate adjusted to a 1-year period; p < 0.001). During the whole follow-up period of 6 months 12 patients (5.0%) were hospitalized due to exacerbations, corresponding to a reduction of 77.5% (p < 0.001). Similarly, unscheduled health care visits and emergency room visits decreased by 80.8% (p < 0.001). Total days patients were not able to go to work or to school were reduced by 71.6% (p < 0.001) (Fig. 1) . Accordingly, there was a marked improvement in quality of life. Mean total score increased to 4.5 AE 1.2 points (p < 0.001) (Fig. 2) .
After 6 months efficacy and tolerability of omalizumab was rated as excellent or good by the majority of physicians (82.2% and 95.0%) and patients (85.9% and 93.7%) ( Table 2 ).
Tolerability and discontinuations
In 100 patients (35.7%) a total of 198 adverse events and in 67 patients (23.9%) a total of 145 severe adverse events (73.2%) were reported. In only 7 of all patients (2.5%) 33 adverse events (16.7% of all AEs) were considered to be related to omalizumab treatment ( Table 3) .
As expected, the respiratory system (37.6%) was the organ system most commonly affected by adverse events, with ''asthma'' being the leading complaint (65 patients).
47 patients (16.8%) discontinued omalizumab treatment after 4 months and 44 patients (18.3%) after 6 months, corresponding to a total discontinuation rate of 32.5%. Main reason for discontinuation was ineffectiveness (48.9% after 4 months, 38.6% after 6 months). Due to the small numbers of patients who discontinued treatment no statistical analyses could be performed to relate insufficient treatment response to a potential overdosing or underdosing of the study drug.
Discussion
Omalizumab has been successfully adopted into clinical practice, with more than 68,000 patients treated worldwide since June 2003. Clinical trials have shown important benefits for many patients with inadequately controlled severe persistent allergic asthma who respond to omalizumab therapy, and demonstrated a good safety profile. This supports the results from the comprehensive clinical trial programme, in which omalizumab significantly reduced asthma exacerbation and emergency visit rates, and significantly improved quality of life in patients with severe 
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After 6 months of omalizumab 1 year prior to omalizumab Figure 2 Mini AQLQ, 7 point score (1 Z always, 2 Z mostly, 3 Z often, 4 Z sometimes, 5 Z rarely, 6 Z hardly ever, 7 Z never). Bars represent points 1e3. Consequently, omalizumab is indicated in the EU as add-on therapy to improve control of severe persistent allergic asthma that remains inadequately controlled despite treatment with high-dose ICS and a LABA. The present study summarizes the clinical experience with omalizumab in a large cohort of German patients with severe allergic asthma following the approval of the drug within the European Union and its launch in Germany. It is the first analysis of the therapeutic effects of omalizumab in a real-life setting in Germany outside of clinical trials.
Several aspects of this study are clinically relevant: In contrast to the controlled trials performed as part of the omalizumab clinical trial program patient recruitment into the present study was not based on in e and exclusion criteria derived from study hypotheses. The patients included in this trail were selected according to the approved European omalizumab label, and, with very few exceptions, the patients' characteristics are well in line with the criteria recommended for the use of omalizumab by the European Medicines Agency (EMEA). 19 This is reflected in the study population by the mean daily dose of inhaled corticosteroids and the high rate of asthma-related events in the year preceding omalizumab treatment. In particular the high rate of exacerbations including emergency visits and hospitalizations highlights the fact that asthma in these patients was uncontrolled despite their already high use of anti-asthmatic medication. Further, the study population reflects both the huge unmet clinical need in patients with severe allergic asthma uncontrolled by guideline-based treatment 2, 22 and the potential for improvement following the institution of guideline-based treatment including omalizumab. Importantly, almost half of the study population was on oral maintenance corticosteroids, an exclusion criterion for most of the phase III omalizumab trials. The results of this trial indicate and confirm preliminary evidence that omalizumab is effective in severe persistent allergic asthma irrespective of concomitant treatment with systemic corticosteroids. 17 Omalizumab can, therefore, be considered for the treatment of inadequately controlled severe persistent allergic asthma, regardless of OCS use.
This was a real-life study reflecting daily clinical practice in an outpatient setting typical for the situation in Germany. In some aspects, the extent of clinical improvement experienced by the majority of patients following treatment with omalizumab was even more pronounced than what was observed in controlled clinical trials. 11, 17 Results similar to what was seen in the German cohort were observed in a comparable situation in France. 23 It is tempting to speculate that controlled studies potentially underestimate the omalizumab effect and overestimate the effects of standard treatment in placebo or comparator arms due to high adherence and expert guidance that is inherent to controlled trials. In a real-life setting adherence in particular to inhaled corticosteroids is notoriously poor 24 while monthly injections that can be scheduled according to the patients' individual needs may favor treatment adherence. The pronounced effect on the rate of severe asthma-related events including hospitalizations is equally relevant in the context of the ongoing discussion about the costeeffectiveness of omalizumab. 25 However, a detailed analysis of cost and effectiveness of this new treatment was beyond the scope of this investigation.
A French historic-prospective study has provided initial data on the real-world effectiveness of omalizumab. In the French study, the annual exacerbation rate decreased by 62%, emergency visits by 65% and hospitalizations by 29% for the 146 patients who had been prescribed omalizumab for severe allergic asthma. Additionally, 48.1% of patients reduced or discontinued maintenance OCS. 23 Analyses of patients treated in clinical trials have shown that it is difficult to predict which patients, within the label population, will derive greatest benefit from omalizumab based on pre-treatment patient characteristics. As recommended in the EU, the most accurate means of ensuring that omalizumab treatment is beneficial to evaluate the 26 Well in line with this experience, 32.5% of patients treated in the present study discontinued omalizumab treatment, mostly due to unsatisfactory therapeutic response. As was seen in the French trial, incorrect dosing may contribute to an insufficient response to the drug. 23 In our cohort, 14.9% of patients who were treated did not fall within the range of the recommended dosing table that considers total IgE concentration and body weight. 27 Potentially, both over-treatment and under-treatment may be explained by the design of the present study which was close to a post-marketing surveillance to give flexibility to the prescriber. However, the small number of patients who discontinued treatment or were incorrectly dosed precluded any statistical analyses to relate insufficient treatment response to a potential overdosing or underdosing of the study drug. Although the potential relationship between under treatment and unsatisfactory therapeutic response could have been formally strengthened at inclusion and follow-up visits, such as an intervention could have modified prescriber behavior and compromise the real-life nature of the study. It is, therefore, essential that the correct dose of omalizumab is calculated and administered for each individual patient.
Finally, the present trial confirmed the favorable safety profile of omalizumab. Frequency and severity of adverse events observed were similar to that seen in the omalizumab phases II and III study program and in many respects comparable to what was reported by patients receiving placebo or best available therapy. 28 This study has several limitations. Clearly, its results strongly suggest that the clinical efficacy of omalizumab demonstrated in randomized controlled trials (RCTs) is reproduced in a real-life setting. The magnitude of the improvements seen when compared with the previous year was at least comparable to that observed in RCTs. However, the results of this trial are based on retrospective comparisons within the same patient population instead of a comparison with a control group or a prospectively defined baseline period. Furthermore, confounding factors such as the placebo effect or a more strict compliance to existing medications due to more frequent physician contacts could not be taken into account. Nevertheless, prescribing practices participating in this trial are representative of the German situation and thus reflect real-life conditions of use.
Another limitation of the study is the way study centers and patients were recruited. In principle, participation in this trial was offered to all German pulmonary and allergy specialists. Neither study centers nor patients fulfill the criteria of a random German sample but represent a selection of physicians who agreed to participate in this trial and who included as many patients as they thought were appropriate. Again, however, the large number of patients makes this sample in many respects representative for the German situation.
Conclusion
In summary, in a German 6-month real-life follow-up study conducted between 2005 and 2007 treatment of 280 patients with severe persistent allergic asthma uncontrolled by inhaled corticosteroids and long-acting b 2 -agonists with omalizumab were generally well tolerated and reduced daily and nocturnal symptoms, asthma exacerbation and emergency visit rates, and improved quality of life. Treatment efficacy was rated as excellent or good by the majority of both physicians and patients, thus confirming the clinically relevant effect of omalizumab.
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